Braveheart Bio, Inc.
Braveheart Bio, Inc. scores highest on Torque (79) and lowest on Price (0). Its PosiPenta is 46.99 out of 100, around the middle of similar companies.
On the Penta Grid this week, Braveheart Bio, Inc. is Grid #338 of 837 in the Healthcare sector in United States, and Grid #2,216 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Braveheart Bio, Inc. | 46.99 | 0 | 39 | 45 | 79 | 72 |
| Xencor, Inc. | 43.38 | 20 | 21 | 78 | 48 | 51 |
| Sarepta Therapeutics, Inc. | 55.43 | 37 | 66 | 62 | 48 | 64 |
| Recursion Pharmaceuticals, Inc. | 42.56 | 28 | 40 | 44 | 50 | 51 |
| LeMaitre Vascular, Inc. | 57.12 | 37 | 59 | 52 | 60 | 78 |
| Septerna, Inc. | 47.77 | 15 | 32 | 75 | 65 | 52 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -3.08 |
| P/B ratio | -17.57 |
EEarnings
| Trailing EPS | ₹-575.87 |
| Forward EPS | ₹-188.48 |
NNitro
| Price | 1772.12 |
| 52-week high | 3030.88 |
| 52-week low | 1691.61 |
| Fall from 52-week high | 41.5% |
TTorque
| Return on equity (ROE) | — |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹15,955 Cr |
| Insider holding | 58.16% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Braveheart Bio, Inc.'s PosiPenta score?
Braveheart Bio, Inc.'s PosiPenta is 46.99 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Braveheart Bio, Inc. stand on the Penta Grid?
On the Penta Grid this week, Braveheart Bio, Inc. is Grid #338 of 837 in the Healthcare sector in United States, and Grid #2,216 of 4,000 in United States.
Which PosiPenta pillar is strongest for Braveheart Bio, Inc.?
Torque (durability), with a score of 79 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Braveheart Bio, Inc.?
Price (valuation), with a score of 0 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.